Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen

K. Gemzell-Danielsson, A. M. Van Heusden, S. R. Killick, H. B. Croxatto, P. Bouchard, S. Cameron, M. Bygdeman

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


Background: The safety and efficacy of the anti-progestogen Org 31710 in improving cycle control in healthy women using the desogestrel progestogen-only pill was investigated in this randomized, double-blind, placebo-controlled study. Methods: A total of 103 women using the 75 μg desogestrel progestogen-only pill daily also received either 150 mg Org 31710 or placebo once every 28 days, starting on day 1, for a duration of 4-7 treatment cycles. Results: The percentage of women with bleeding or spotting (B/S) every day in the placebo group was on average 30% during the whole treatment period and no days without reported B/S occurred. In contrast, a cyclic pattern was observed for the Org 31710 group; a peak incidence of B/S was observed on day 3 or 4 of each cycle, followed by a sharp decrease on cycle days 9-15. Compared with controls, less subjects in the Org 31710 group reported irregular, frequent or prolonged bleeding. These differences were clearly observed in the initial cycles, but were somewhat less pronounced during the later cycles of the treatment period. A relatively high incidence of B/S episodes starting in the second section of the cycle was also observed. Conclusion: The addition of Org 31710 once a month improved cycle control in women using daily treatment with 75 μg desogestrel.

Original languageEnglish
Pages (from-to)2588-2593
Number of pages6
JournalHuman Reproduction
Issue number10
Publication statusPublished - 1 Oct 2002


  • Anti-progestogens
  • Cycle control
  • Progestogen-only pill

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology


Dive into the research topics of 'Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen'. Together they form a unique fingerprint.

Cite this